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We investigated the incidence of granuloma and its related factors in 180 patients with prostate cancer
who showed subcutaneous granuloma formation during androgen deprivation therapy with subcutaneously
administered leuprorelin acetate. A granuloma was defined as a persistent induration over 30 mm in
diameter in the injected portion. Small indurations which often developed and disappeared after every
injection were excluded. The survey was performed using a questionnaire after receiving written informed
consent. Among the 180 patients with prostate cancer, 21 (11.7%) developed a granuloma at the injection
portion, and subsequently the injection of leuprorelin acetate had to be discontinued. Eighteen of the 21
patients alternatively received goserelin acetate. Three patients had high-grade granulomas with ulcer and
abscess formation, and were successfully treated with oral antibiotics. The average duration between the
first injection of leuprorelin acetate and granuloma formation was 20.2 months (range : 4 to 62 months).
There was no association between granuloma formation and patient backgrounds, such as allergic
predisposition and past history. Twenty-one of the 180 prostatic cancer patients developed subcutaneous
granuloma induced by the injection of leuprorelin acetate. The investigation showed an unexpectedly high
incidence of granuloma formation. We must explain the risk of developing subcutaneous granuloma to the
patients before introducing leuprorelin acetate.
(Hinyokika Kiyo 61 : 55-59, 2015)










































臨床病期 : Stage ( )
LH-RH 治療期間 : ケ月
LH-RH 前治療 : あり（ ），なし
LH-RH 製剤 : 1，3カ月製剤
投与部位 : 上腕，腹部，でん部，その他（ )
硬結形成 : あり（出現までの投与回数 ; ），なし
潰瘍・腫瘍形成 :
あり（出現までの投与回数 ; ），なし







食物アレルギー : あり（ ），なし
糖尿病 : あり，なし
高血圧 : あり，なし
膠原病 : あり（ ），なし
ケロイド体質 : あり，なし
ケロイド体質の家族歴 : あり，なし
その他の合併症 ; あり（ ），なし
喫煙歴 : あり，なし
飲酒歴 : あり，なし
Fig. 1. The questionnaire to evaluate the relation-
ship between allergic predisposition or past
history of the patients with prostate cancer
and injection-site granuloma induced by
subcutaneous injection of leuproreline ace-
tate.
Table 1. Characteristics of the patients with pros-
tate cancer administered leuproreline ace-
tate for androgen deprivation therapy
診断時年齢 74.5±6.3歳（57-92)



















有無の群間比較では Mann-Whitney test を用い，危険





均74.5歳で，診断時 PSA は 4.0∼3,770 ng/ml（中央
値 24.4 ng/ml）であった．11例が前立腺全摘除術後
の PSA 再発症例で， 7 例が放射線外照射療法後の
PSA 再発症例であった．観察期間内に使用していた
酢酸リュープロレリンは， 1カ月製剤（3.75 mg）が
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Table 2. Characteristics of the patients with pros-
tate cancer with or without injection-site
granuloma induced by subcutaneous






（平均±SD) 76.3±5.8歳 74.3±6.4歳 0.18
✝
診断時 PSA





※ : 放射線外照射 4例，※※ : 前立腺全摘11例，放射線外
照射 3例，✝ : Mann-Whitney test，* : Fisher’s exact test．
Table 3. Characteristics of the patients with pros-
tate cancer with or without injection-site
granuloma in terms of allergic predis-





気管支喘息 1/20 11/148 0.71
アレルギー性鼻炎 0/21 4/155 1.0
アトピー性皮膚炎 0/21 5/154 1.0
花粉症 1/20 37/122 0.08
テープかぶれ 2/19 20/139 0.69
食物アレルギー 0/21 3/156 1.0
糖尿病 2/19 30/129 0.38
高血圧 11/10 81/ 78 0.90
膠原病 0/21 2/157 1.0
ケロイド体質 1/20 2/157 0.31
喫煙歴 8/13 43/116 0.31
飲酒歴 14/ 7 89/ 70 0.48
(あり/なし) (あり/なし)






で， 1 カ月製剤（3. 75 mg）と 3 カ月製剤（11. 25
mg）がある． 1カ月製剤は1992年に， 3カ月製剤は
2002年に市販された． 1カ月製剤は，乳酸グルコール




RH の約100倍の活性をもつ LH-RH アゴニスト製剤
が持続的に生体に吸収される状態をつくることによ
り，視床下部において LH-RH 受容体の down regula-
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